Navigation Links
First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive
Date:12/16/2009

ranging between $500 million and $750 million from 2011 to 2015. If you add the additional applications such as facelift, breast reconstruction and body contouring that we will pursue with TissuGlu, the opportunity increases to between $700 million to more than $1 billion over the same five-year period."

Chad Coberly, J.D., vice president of clinical, regulatory and legal affairs of Cohera Medical, added: "Initiation of this study culminates significant preclinical work by our company and investigators and demonstrates the primary safety profile of this product. This study will enable us to move closer to CE Mark application in Europe and will provide important data in application for a larger U.S.-based trial in 2010."

Preclinical data published in the July 2008 issue of Plastic and Reconstructive Surgery show that TissuGlu prevented seroma formation in an animal abdominoplasty model. Summarized in a paper titled "Lysine-Derived Urethane Surgical Adhesive Prevents Seroma Formation in a Canine Abdominoplasty Model," (Plast. Reconstr. Surg. 2008; Vol. 122, Issue 1: 95-102) the results demonstrated that TissuGlu successfully prevented the formation of seroma in a novel large-animal model designed to evaluate seroma formation. While the control side in all seven animals used in the study demonstrated large, clinically significant seromas, the side treated with TissuGlu showed little or no evidence of fluid accumulation. In addition, histologic analysis of tissue samples from the animals showed no signs of inflammation or foreign body reaction associated with the adhesive.

"The progress with the development of TissuGlu represents a significant next step in the value creation for Cohera Medical's investors," said Doros Platika, M.D., the company's chairman. "Most importantly, it signifies a potential major advance for surgical patients that may help to decrease complications and improve clinical outcomes." '/>"/>

SOURCE Cohera Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The scientific team of a new ... the leading academics in the field of aging Prof. ... life extension for model animals - 10 fold for nematodes) ... age-related diseases, primarily, around the stability and stress resistance of ... as "Stability analysis of a model gene network links aging, ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
(Date:8/28/2015)... SAN FRANCISCO , August 28, 2015 ... is expected to reach USD 49.12 billion by 2020, ... 2020, according to a new report by Grand View ... an estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... 2011  Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today ... edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly ... total knee or hip arthroplasty, when compared to enoxaparin. ... composite of deep vein thrombosis (DVT) and pulmonary embolism ...
... SHANGHAI, Dec. 12, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: ... medical-device research and development outsourcing company with operations in ... of its fifth Life Science and Chemistry Awards, held ... Beijing. The theme of this year,s awards ...
Cached Medicine Technology:Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 2Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 3Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 4Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 5WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 2WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 3
(Date:8/29/2015)... ... ... Rio Salado College President Chris Bustamante announced on Aug. 19 ... Initiatives and Information Services. O’Shea, who has served Rio Salado for the last two ... through innovative technologies and strategies. , “I am very proud to be able to ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... to insufficient scrotal support and protection against dribbled urine and sweat. "In order ... Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/28/2015)... ... 29, 2015 , ... Rio Salado College joined nine educational institutions ... part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published ... maker Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco ... tends to take several months, but the current process, having already gone on for ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2
... A HIV protease inhibitor Aptivus ( tipranavir ) , has ... // . The capsules are to be given in combination ... the second drug approved for patients with advanced HIV disease, ... options., ,The benefits of Aptivus in combination with ritonavir, ...
... on bipolar disorder conducted by the World Federation for ... feel that their quality of life suffers because of ... characterized by successive feelings of elation and depression. Also ... 5 of the global adult population. This is a ...
... may be reacting to varying degrees of energy loss during ... genetic predisposition. How our bodies react to exercise programs is ... exercising like the level of blood glucose in the body ... of scientists from Washington University School of Medicine, exercise can ...
... around now for almost 40 years for treatment skin ... maybe useful in treating cancer as it has been shown ... was reported by international team of scientists. Leslie Wilson, professor ... Barbara, The results are published in online edition of the ...
... time in India ,German Remedies, a part of the Zydus ... of chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia (CLL) is a ... which at present has no cure. The disease is unknown ... more common with increasing age. ,Fludarabine has emerged ...
... Researchers have found that teenage girls living in temperate countries ... in life if they took supplements of Vitamin D in ... is low. The sun is important for formation of the ... ,The vitamin supplement would help to strengthen bones for later ...
Cached Medicine News:Health News:Vitamin D Supplement in Teenage Girls essential in Winter months 2
... drainage set (EVD set) drains ... external ventricular drainage. It can ... a ventricular catheter or with ... from the Aesculap Spiegelberg ICP, ...
... The CODMAN EDS 3 CSF External Drainage ... 200 nurses and physicians. The clinicians who work ... distinguish the CODMAN EDS 3: ease-of-use in an ... SPLASHFREE valve, accurate hydrostatic leveling from a ...
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Monitorr ICP external CSF drainage and monitoring system with patient line one way valve....
Medicine Products: